Marjolein S. de Bruin-Weller

Marjolein S. de Bruin-Weller publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Marjolein S. de Bruin-Weller sits on this spectrum.

Marjolein S. de Bruin-Weller D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Marjolein S. de Bruin-Weller sits on this spectrum.

Best Publications

• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

  Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  1357
  Citations

• Epidemiology of atopic dermatitis in adults: Results from an international survey.

  S. Barbarot;S. Auziere;A. Gadkari;G. Girolomoni

  864
  Citations

• Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

  M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  523
  Citations

• ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.

  A. Wollenberg;Arnold Oranje;M. Deleuran;D. Simon

  495
  Citations

• ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

  A. Wollenberg;S. Christen-Zäch;A. Taieb;Carle Paul

  431
  Citations

• Conjunctivitis in dupilumab clinical trials.

  B. Akinlade;E. Guttman-Yassky;M. de Bruin-Weller;E. L. Simpson

  423
  Citations

• Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis

  J. M. Oldhoff;U. Darsow;T. Werfel;K. Katzer

  376
  Citations

• Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.

  Kristian Reich;Henrique D Teixeira;Marjolein de Bruin-Weller;Thomas Bieber

  360
  Citations

• Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis

  DirkJan Hijnen;Marjolein de Bruin-Weller;Bert Oosting;Cristina Lebre

  261
  Citations

• When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

  Eric L. Simpson;Marjolein Bruin-Weller;Carsten Flohr;Michael R. Ardern-Jones

  249
  Citations

• Biomarkers for atopic dermatitis: a systematic review and meta-analysis.

  Judith Thijs;Todor Krastev;Stephan Weidinger;Constantinus F Buckens

  248
  Citations

• Dupilumab Shows Long-Term Safety and Efficacy in Patients With Moderate to Severe Atopic Dermatitis Enrolled in a Phase 3 Open-Label Extension Study

  Mette Deleuran;Diamant Thaçi;Lisa A. Beck;Marjolein de Bruin-Weller

  246
  Citations

• Towards global consensus on outcome measures for atopic eczema research: Results of the HOME II meeting

  Jochen Schmitt;Phyllis Spuls;Maarten Boers;Kim Thomas

  222
  Citations

• Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial.

  Inge M. Haeck;Mirjam J. Knol;Onno ten Berge;Sara G.A. van Velsen

  221
  Citations

• Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment

  Andreas Wollenberg;Lieneke Ariens;Stephan Thurau;Chantal van Luijk

  203
  Citations

• Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

  Lawrence F. Eichenfield;Lawrence F. Eichenfield;Thomas Bieber;Lisa A. Beck;Eric L. Simpson

  186
  Citations

• Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.

  A.M. Drucker;A.M. Drucker;A.M. Drucker;K. Eyerich;M.S. de Bruin-Weller;J.P. Thyssen

  184
  Citations

• Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.

  Judith L. Thijs;Ian Strickland;Carla A.F.M. Bruijnzeel-Koomen;Stefan Nierkens

  175
  Citations

• Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: The Dutch Mite Avoidance Study

  Albert-Jan Oosting;Marjolein S. de Bruin-Weller;Ingrid Terreehorst;Zana Tempels-Pavlica

  163
  Citations

• Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

  D S Bakker;L F M Ariens;C van Luijk;J van der Schaft

  149
  Citations